CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed. In this 26-week, double-blind trial of 72 adults, 36% who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback